Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

Background: Despite a potentially curative treatment, the prognosis after upfront surgery and adjuvant chemotherapy for patients with resectable pancreatic ductal adenocarcinoma (PDAC) is poor. Modified FOLFIRINOX (mFOLFIRINOX) is a cornerstone in the systemic treatment of PDAC, including the neoa...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Vilalta, A. (Anna), Aldaz, A. (Azucena), Sala-Elarre, P. (Pablo), Urrizola-Martínez, A. (Amaia), Chopitea, A. (Ana), Arbea-Moreno, L. (Leire), Rotellar, F. (Fernando), Pardo, F. (Fernando), Marti-Cruchaga, P. (Pablo), Zozaya-Larequi, G. (Gabriel), Subtil, J.C. (José Carlos), Rodríguez-Rodríguez, J. (Javier), Ponz-Sarvise, M. (Mariano)
Fformat: info:eu-repo/semantics/article
Iaith:eng
Cyhoeddwyd: Elsevier 2023
Pynciau:
CPT-11
Pharmacokinetics
5-Fluorouracil
Pancreatic ductal adenocarcinoma
Mynediad Ar-lein:https://hdl.handle.net/10171/67542

Rhyngrwyd

https://hdl.handle.net/10171/67542

Eitemau Tebyg